CXCR4 and lymphopenia: These data demonstrate that prolonged treatment with CXCR4 antagonist X4-185 corrected splenic B-cell abnormalities in Cxcr4+/1013 mice, while normalizing B-cell lymphopenia in the peripheral blood.